Sign In
Buy OVAS
$3.26
+0 (+0%)
At Close: Dec 08, 2023
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
07:00am, Thursday, 09'th Aug 2018
WALTHAM, Mass. & ANN ARBOR, Mich.--(BUSINESS WIRE)--OvaScienceSM (Nasdaq:OVAS) and privately-held Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel tr
OvaScience to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call
04:02pm, Thursday, 08'th Mar 2018
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScience℠ (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with inf
OvaScience to Host Third Quarter 2017 Financial Results Conference Call
04:02pm, Thursday, 26'th Oct 2017
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will hos
OvaScience to Host Second Quarter 2017 Financial Results Conference Call
07:00am, Thursday, 27'th Jul 2017
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will hos
OvaScience to Host First Quarter 2017 Financial Results Conference Call
04:02pm, Tuesday, 02'nd May 2017
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it w
OvaScience to Host Fourth Quarter and Fiscal Year 2016 Financial Results Conference Call
04:01pm, Thursday, 23'rd Feb 2017
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it w
OvaScience to Host Third Quarter 2016 Financial Results Conference Call
04:01pm, Thursday, 27'th Oct 2016
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it w
OvaScience to Host Second Quarter 2016 Financial Results Conference Call
04:05pm, Thursday, 28'th Jul 2016
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it w
OvaScience to Host First Quarter 2016 Financial Results Conference Call
04:00pm, Thursday, 28'th Apr 2016
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it w
OvaScience to Host Fourth Quarter and Fiscal Year 2015 Financial Results Conference Call
04:00pm, Thursday, 18'th Feb 2016
WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it w
OvaScience Provides Update on Corporate Goal for AUGMENT Treatment
06:30pm, Monday, 28'th Sep 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that th
CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that a
CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today a confe
